Table 4.

Angiogenic profile of hematologic malignancies.

Angiogenic Receptors
MalignancyPro-Angiogenic MoleculesMVDVEGFR-1VEGFR-2FGF-RClinical/Biological CorrelationReference
Abbreviations: CR, complete remission; s, serum or plasma; u, urinary; c, cellular; CRP, C-reactive protein; B2M, beta2-microglobulin; LN, lymph node; MMM, myelofibrosis with myeloid metaplasia; Unk, unknown; IL-6, interleukin-6; ALIP, abnormal localized immature precursors; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MVD, microvessel density; OS, overall survival; DFS, disease-free survival; BM, bone marrow; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; bFGF, basic FGF; SDF-1, stromal-derived factor 1 
* Denotes independent prognostic factor. 
AML s,cVEGF* ↑BM ++ +/- Unk Leukocytosis; ↓CR*, OS*, DFS* (VEGF) 68,69,71,72,78, 94-96 
 cMMP 2,9       
 sFGF       
 sSDF-1       
MDS VEGF ↑BM ++ +/- Unk Survival (VEGF); 69,72,96-9 
 cMMP-2,cMMP-9     blast % (MVD);  
 sSDF-1     TNFα generation; ALIP  
 sIL-8       
MMM  ↑BM Unk Unk Unk Survival (MVD)* 99 
      Splenomegaly (MVD)  
Myeloma s,cVEGF ↑BM Overall survival (MVD) 20,74,100-102 
 sbFGF*     Trisomy 13, CRP, B2 
 cMMP-2     ↑ stromal IL-6  
ALL s,ubFGF ↑BM Unk Unk Unk  72,103,104 
 sSDF-1       
 cMMP-2,cMMP-9       
NHL sbFGF* ↑LN +/- Unk Survival* (VEGF, FGF) 75-77,105,106 
 s,cVEGF*     High grade histology (VEGF, FGF)  
      Advanced stage  
CLL s,cVEGF ↑BM Unk Unk Advanced stage (MVD, VEGF) 72,73,107-109 
 c,sbFGF     Time to progression (VEGF)  
 sSDF-1     Fludarabine resistance (cFGF)  
CML sVEGF ↑BM Unk Unk  72,73 
 c,sbFGF       
 sSDF-1       
Angiogenic Receptors
MalignancyPro-Angiogenic MoleculesMVDVEGFR-1VEGFR-2FGF-RClinical/Biological CorrelationReference
Abbreviations: CR, complete remission; s, serum or plasma; u, urinary; c, cellular; CRP, C-reactive protein; B2M, beta2-microglobulin; LN, lymph node; MMM, myelofibrosis with myeloid metaplasia; Unk, unknown; IL-6, interleukin-6; ALIP, abnormal localized immature precursors; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MVD, microvessel density; OS, overall survival; DFS, disease-free survival; BM, bone marrow; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; bFGF, basic FGF; SDF-1, stromal-derived factor 1 
* Denotes independent prognostic factor. 
AML s,cVEGF* ↑BM ++ +/- Unk Leukocytosis; ↓CR*, OS*, DFS* (VEGF) 68,69,71,72,78, 94-96 
 cMMP 2,9       
 sFGF       
 sSDF-1       
MDS VEGF ↑BM ++ +/- Unk Survival (VEGF); 69,72,96-9 
 cMMP-2,cMMP-9     blast % (MVD);  
 sSDF-1     TNFα generation; ALIP  
 sIL-8       
MMM  ↑BM Unk Unk Unk Survival (MVD)* 99 
      Splenomegaly (MVD)  
Myeloma s,cVEGF ↑BM Overall survival (MVD) 20,74,100-102 
 sbFGF*     Trisomy 13, CRP, B2 
 cMMP-2     ↑ stromal IL-6  
ALL s,ubFGF ↑BM Unk Unk Unk  72,103,104 
 sSDF-1       
 cMMP-2,cMMP-9       
NHL sbFGF* ↑LN +/- Unk Survival* (VEGF, FGF) 75-77,105,106 
 s,cVEGF*     High grade histology (VEGF, FGF)  
      Advanced stage  
CLL s,cVEGF ↑BM Unk Unk Advanced stage (MVD, VEGF) 72,73,107-109 
 c,sbFGF     Time to progression (VEGF)  
 sSDF-1     Fludarabine resistance (cFGF)  
CML sVEGF ↑BM Unk Unk  72,73 
 c,sbFGF       
 sSDF-1       
Close Modal

or Create an Account

Close Modal
Close Modal